Fulltext

A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

Al-Hatamleh MAI 1 , Ahmad S 1 , Boer JC 2 , Lim J 3 , Chen X 4 , Plebanski M 5 Show all authors , Mohamud R 1

Affiliations 

  • 1 Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan 16150, Malaysia
  • 2 Department of Immunology and Pathology, Monash University, Melbourne 3168, Australia
  • 3 School of Chemical Engineering, Universiti Sains Malaysia, Penang 14300, Malaysia
  • 4 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, China
  • 5 School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia
J Oncol, 2019;2019:6313242.
PMID: 31239840 DOI: 10.1155/2019/6313242

Abstract

In the past decade, nanomedicine research has provided us with highly useful agents (nanoparticles) delivering therapeutic drugs to target cancer cells. The present review highlights nanomedicine applications for breast cancer immunotherapy. Recent studies have suggested that tumour necrosis factor (TNF) and its receptor 2 (TNFR2) expressed on breast cancer cells have important functional consequences. This cytokine/receptor interaction is also critical for promoting highly immune-suppressive phenotypes by regulatory T cells (Tregs). This review generally provides a background for nanoparticles as potential drug delivery agents for immunomodulators and further discusses in depth the potential of TNF antagonists delivery to modulate TNF-TNFR2 interactions and inhibit breast cancer progression.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications